Search results
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
Zacks via Yahoo Finance· 19 hours agoEvery day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and...
Biogen Inc. (NASDAQ:BIIB) Stock Position Trimmed by Stephens Inc. AR
ETF DAILY NEWS· 5 days agoStephens Inc. AR cut its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 2.8% during the 4th quarter, according to the company in its most recent filing with the Securities ...
Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
Zacks via Yahoo Finance· 4 days agoFDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of...
Biogen executive plays down looming competition for its Alzheimer's drug
Reuters via AOL· 2 days ago(Reuters) -Biogen's Alzheimer's drug, Leqembi, will do well in the market whether a competitor comes...
Gabelli Funds LLC Has $3.80 Million Stock Position in Biogen Inc. (NASDAQ:BIIB)
ETF DAILY NEWS· 5 days agoGabelli Funds LLC trimmed its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 0.5% during the fourth quarter, according to its most recent disclosure with the ...
Biogen Inc. Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges BIIB Investors with Losses to...
Morningstar· 4 days agoThe law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District ...
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
CNBC· 3 days agoThe FDA typically follows the recommendations of its advisory panels but is not required to do so....
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class...
Morningstar· 4 days agoDo you, or did you, own shares of Biogen Inc. (NASDAQ: BIIB)? Did you lose money in your investment in Biogen Inc.? Bernstein Liebhard LLP announces that ...
Biogen executive says its Alzheimer’s drug will do well in market despite competition
WHTC 1450 Holland· 2 days ago(Reuters) - Biogen's Alzheimer's drug, Leqembi, will do well in the market, whether a competitor...
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Crossmark Global Holdings Inc.
ETF DAILY NEWS· 6 days agoCrossmark Global Holdings Inc. decreased its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 19.1% during the 4th quarter, HoldingsChannel reports. The institutional ...